文献速递类风湿关节炎

早期类风湿关节炎是否应使用糖皮质激素:UCLouvain Brussels队列5年结果

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于UCLouvain Brussels早期RA队列474例未用过cDMARDs的患者,回顾分析启动与未启动糖皮质激素者的基线特征及5年疗效与严重不良事件。结果显示两组5年DAS28-CRP、HAQ、VAS疼痛无差异;累积泼尼松龙>1 g亚组中DAS28-CRP、VAS疼痛、HAQ持续更高且严重感染更多。

要点

  • 早期RA启动糖皮质激素未带来短期或长期额外疾病控制获益。
  • 糖皮质激素更多用于CRP升高、吸烟、ACPA阴性、MTX单药及年龄较大的患者。
  • 5年内泼尼松龙累积>1 g者疾病活动与功能评分更高、严重感染更多。

核心结论

  • 在該早期RA队列中,启动糖皮质激素治疗未对短期和长期疾病控制带来额外获益。
  • 糖皮质激素更多被处方于炎症水平更高的血清阴性RA患者。

研究设计与样本

  • UCLouvain Brussels队列回顾性研究,纳入符合ACR/EULAR 2010分类标准且未用过cDMARDs的早期RA患者474例。
  • 比较启动糖皮质激素180例与未启动294例,并在6、12、36、60个月分析疗效与严重不良事件。

主要发现

  • 两组5年随访的DAS28-CRP、HAQ或VAS疼痛值无差异。
  • 基线时CRP升高是促使启动糖皮质激素的主要因素,其次为吸烟、ACPA阴性、MTX单药治疗和年龄。
  • 5年内接受>1 g泼尼松龙的139例亚组基线男性更多、DAS28-CRP更高,随访中DAS28-CRP、VAS疼痛和HAQ持续显著更高,并报告更多严重感染。

临床怎么用

  • 对早期RA不应常规以糖皮质激素作为改善疾病控制的附加手段,尤其血清阴性且炎症明显者需权衡感染风险。

局限性

  • 为回顾性队列研究,糖皮质激素启动非随机分配,可能存在适应证混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the proportion of patients with early RA (ERA) who had or had not initiated glucocorticoids, to analyse the baseline characteristics, and to assess the clinical benefit and side effects of glucocorticoids during 5 years of follow-up. METHODS: We included patients with ERA from the UCLouvain Brussels cohort who met the ACR/EULAR 2010 classification criteria and were naïve to conventional DMARDs (cDMARDs). We retrospectively collected patient characteristics prior to the introduction of cDMARDs with or without glucocorticoids. Efficiency and serious adverse events were analysed at 6, 12, 36 and 60 months. RESULTS: Data from 474 eligible ERA patients were collected; 180 patients initiated glucocorticoids compared with 294 who did not. At baseline, the increased CRP was the main factor that favoured the initiation of glucocorticoids followed by smoking, absence of ACPA, prescription of MTX as a monotherapy and age. Five years' follow-up of DAS28-CRP, HAQ or visual analog score (VAS) pain values did not differ between the two groups. We also analysed a subgroup of 139 patients who received >1 g of prednisolone during the 5-year period. We confirmed the same baseline differences and observed in addition more men and higher DAS-28CRP values. During the 5 years' follow-up, DAS-28CRP, VAS pain and HAQ remained significantly higher in this subgroup. More severe infections were also reported. CONCLUSION: In our ERA cohort, the initiation of glucocorticoid treatment did not bring additional benefit for the short- and long-term control of the disease. Glucocorticoid was more prescribed in seronegative RA patients with a higher level of inflammation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sapart E, Sokolova T, de Montjoye S, et al. Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort. Rheumatology (Oxford). 2021. PMID: 33605405. doi:10.1093/rheumatology/keab151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。